Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of oral emetine in patients aged 18 to 65 years who have symptomatic dengue fever. This study aims to determine whether emetine can reduce 28-day mortality or progression to severe dengue, including severe plasma leakage, bleeding, or organ involvement. It also assesses the safety of emetine, including serious side effects and toxicities. Dengue fever is a significant global health concern transmitted by mosquitoes, with no proven antiviral treatment currently available, and this study explores emetines potential as an antiviral agent. Participants will receive one of three treatments 6 mg emetine, 12 mg emetine, or a placebo pill taken orally for 10 consecutive days. The study is randomized, double-blinded, and placebo-controlled, ensuring unbiased assessment across groups. Blood samples will be collected for at least five days to monitor viral load, inflammatory markers, and safety parameters. The research builds on previous studies indicating emetines antiviral activity at low doses without significant cardiovascular toxicity. During the study, participants will be monitored daily by healthcare staff who will record vital signs and symptoms for clinical assessments over 28 days. Blood tests will measure changes in viral load and various inflammatory markers, while questionnaires will assess fatigue after infection on day 28. The primary outcomes focus on mortality, disease progression, and safety events within 28 days. Participants will be closely followed to track recovery time, viral clearance, and any adverse reactions throughout the trial.
Actively Recruiting
The ICU-related Out-of-Pocket Expenses ICOPE study is a multinational, prospective observational study conducted in African and Asian countries to understand the financial impact of ICU care on patients and their families. The study focuses on measuring out-of-pocket expenses and the occurrence of catastrophic health expenditure among patients who stay in the ICU for more than 24 hours, including those who receive mechanical ventilation and those who do not. The study addresses the rising cost burden related to ICU care in low- and middle-income countries LMICs and aims to identify factors contributing to financial hardship. Participants include all patients admitted to participating ICUs during a 14-day recruitment period, with a planned sample size of at least 354 patients. The study compares groups of patients receiving invasive mechanical ventilation with those who do not, tracking their ICU-related expenses. The follow-up period extends from ICU admission to discharge, with additional assessments at 30 days and 6 months, spanning a total study duration of 18 months. During the study, researchers will collect detailed information about direct and indirect costs associated with ICU care, including medical and non-medical expenses. They will also examine how families cope with these costs and identify risk factors for catastrophic health expenditure. The primary outcomes include out-of-pocket cost per patient episode and the relative risk of catastrophic health expenditure by ICU discharge. Secondary outcomes include risk factors for catastrophic expenditure and the frequency of various coping strategies used by families.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.